These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17722083)

  • 1. Stability and hydrolysis kinetics of spirosuccinimide type inhibitors of aldose reductase in aqueous solution and retardation of their hydrolysis by the target enzyme.
    Kurono M; Itogawa A; Noguchi H; Sanjoba M
    J Pharm Sci; 2008 Apr; 97(4):1468-83. PubMed ID: 17722083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: a significant role of specific binding by serum albumin in the improved potency and stability.
    Kurono M; Fujii A; Murata M; Fujitani B; Negoro T
    Biochem Pharmacol; 2006 Jan; 71(3):338-53. PubMed ID: 16324683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase.
    Kurono M; Fujiwara I; Yoshida K
    Biochemistry; 2001 Jul; 40(28):8216-26. PubMed ID: 11444967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.
    Negoro T; Murata M; Ueda S; Fujitani B; Ono Y; Kuromiya A; Komiya M; Suzuki K; Matsumoto J
    J Med Chem; 1998 Oct; 41(21):4118-29. PubMed ID: 9767647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mechanistic and kinetic study of the beta-lactone hydrolysis of Salinosporamide A (NPI-0052), a novel proteasome inhibitor.
    Denora N; Potts BC; Stella VJ
    J Pharm Sci; 2007 Aug; 96(8):2037-47. PubMed ID: 17554770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epimer interconversion, isomerization, and hydrolysis of tetrahydrouridine: implications for cytidine deaminase inhibition.
    Xiang TX; Niemi R; Bummer P; Anderson BD
    J Pharm Sci; 2003 Oct; 92(10):2027-39. PubMed ID: 14502542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative structure-activity relationship of spirosuccinimide type aldose reductase inhibitors diminishing sorbitol accumulation in vivo.
    Ko K; Won H; Won Y
    Bioorg Med Chem; 2006 May; 14(9):3090-7. PubMed ID: 16412651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications.
    Giannoukakis N
    Curr Opin Investig Drugs; 2006 Oct; 7(10):916-23. PubMed ID: 17086937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative structure and aldose reductase inhibitory activity relationship of 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone derivatives.
    Ko K; Won Y
    Bioorg Med Chem; 2005 Mar; 13(5):1445-52. PubMed ID: 15698760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of hydrolysis of a novel indolocarbazole topoisomerase I inhibitor.
    Breslin D; Sato Y; Karki SB
    Eur J Pharm Sci; 2010 Mar; 39(5):291-7. PubMed ID: 20025967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.
    Giannoukakis N
    Expert Opin Investig Drugs; 2008 Apr; 17(4):575-81. PubMed ID: 18363521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivity of valganciclovir in aqueous solution.
    Stefanidis D; Brandl M
    Drug Dev Ind Pharm; 2005 Oct; 31(9):879-84. PubMed ID: 16305999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical stability and fate of the cytostatic drug ifosfamide and its N-dechloroethylated metabolites in acidic aqueous solutions.
    Gilard V; Martino R; Malet-Martino M; Niemeyer U; Pohl J
    J Med Chem; 1999 Jul; 42(14):2542-60. PubMed ID: 10411475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics and molecular docking studies of an anti-diabetic complication inhibitor fucosterol from edible brown algae Eisenia bicyclis and Ecklonia stolonifera.
    Jung HA; Islam MN; Lee CM; Oh SH; Lee S; Jung JH; Choi JS
    Chem Biol Interact; 2013 Oct; 206(1):55-62. PubMed ID: 23994501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carboxymethylated pyridoindole antioxidants as aldose reductase inhibitors: Synthesis, activity, partitioning, and molecular modeling.
    Stefek M; Snirc V; Djoubissie PO; Majekova M; Demopoulos V; Rackova L; Bezakova Z; Karasu C; Carbone V; El-Kabbani O
    Bioorg Med Chem; 2008 May; 16(9):4908-20. PubMed ID: 18395454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics and mechanism of hydrolysis of N-acyloxymethyl derivatives of azetidin-2-one.
    Valente E; Gomes JR; Moreira R; Iley J
    J Org Chem; 2004 May; 69(10):3359-67. PubMed ID: 15132543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preformulation study of methazolamide for topical ophthalmic delivery: physicochemical properties and degradation kinetics in aqueous solutions.
    Jiang S; Wang F; Zhu S; Zhang X; Guo Z; Li R; Xu Q
    Int J Pharm; 2013 May; 448(2):390-3. PubMed ID: 23541985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability of cefozopran hydrochloride in aqueous solutions.
    Zalewski P; Skibiński R; Paczkowska M; Garbacki P; Talaczyńska A; Cielecka-Piontek J; Jelińska A
    Drug Dev Ind Pharm; 2016; 42(4):572-7. PubMed ID: 26079426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of new potential ACE inhibitor in the aqueous solutions of different pH.
    Roskar R; Simoncic Z; Gartner A; Kmetec V
    J Pharm Biomed Anal; 2009 Feb; 49(2):295-303. PubMed ID: 19135817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methocarbamol degradation in aqueous solution.
    Pouli N; Antoniadou-Vyzas A; Foscolos GB
    J Pharm Sci; 1994 Apr; 83(4):499-501. PubMed ID: 8046603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.